Company news

Telix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20, 2025

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

June 19, 2025

Telix Investor Day Presentation

June 11, 2025

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

June 3, 2025

Telix to Host Investor Day in New York City on June 11, 2025

May 22, 2025

Telix at ANZSNM Annual Scientific Meeting 2025

May 19, 2025

Illuccix China Phase 3 Study Completes Enrolment

May 12, 2025

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28, 2025

Telix Provides Regulatory Update on TLX101-CDx

April 27, 2025

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025

FDA Approves New Prostate Cancer Imaging Agent Gozellix

March 20, 2025

Telix Completes FAP-Targeting Theranostic Acquisition

March 11, 2025

FDA accepts BLA and grants priority review for Zircaix

February 25, 2025

Telix Announces Change in Reporting Currency to USD

February 24, 2025

2024 Full Year Results Presentation

February 20, 2025

2024 Full Year Results Announcement

February 20, 2025

Appendix 4E and 2024 Annual Report

February 20, 2025

Illuccix Approved in the United Kingdom

February 12, 2025

Telix Completes Acquisition of Tx Assets, Biologics Platform

January 30, 2025

Telix Completes Acquisition of RLS (USA) Inc

January 27, 2025

Illuccix Receives European Approval

January 16, 2025

Telix JP Morgan Healthcare Conference 2025 Presentation

January 13, 2025

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

January 13, 2025

Presentation to Accompany Biologics Platform Acquisition

January 12, 2025

TLX to Acquire Next-Gen Therapeutics and Biologics Platform

January 12, 2025

Presentation to Accompany FAP-Targeting Acquisition

November 18, 2024

Telix Adds FAP-Targeting Theranostic Candidates to Pipeline

November 18, 2024

CMS payment improvement decision for radiopharma diagnostics

November 3, 2024

FDA accepts NDA and grants priority review for Pixclara

October 23, 2024

Telix Files Form 20-F Registration Statement for Nasdaq ADS

October 17, 2024

Telix Q3 2024 Revenue and Business Update

October 17, 2024

Telix to Acquire RLS for US Manufacturing and Distribution

September 22, 2024

Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent

August 27, 2024

Telix 1H 2024 Results Release

August 22, 2024

Telix 1H 2024 Results Presentation

August 22, 2024

Telix 1H 2024 Appendix 4D and Interim Report

August 22, 2024

Telix Completes A$650 Million of Convertible Bonds

July 30, 2024

Convertible Bond Cleansing Notice

July 29, 2024

Telix Successfully Prices A$650M Convertible Bonds

July 23, 2024

Telix Announces A$600 Million Convertible Bonds Offering

July 23, 2024

Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade

July 17, 2024

CMS proposes payment improvement for radiopharma diagnostics

July 11, 2024

Telix Elects to Withdraw from Proposed U.S. Listing

June 13, 2024

Trading Halt

June 12, 2024

Telix Launches Proposed US IPO

June 5, 2024

Telix Completes TLX250-CDx (Zircaix) BLA Submission

June 2, 2024

ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS

May 30, 2024

Response to ASX Query

May 28, 2024

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 57 decks. Every deck is listed under its year.